title: Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis.
abstract: To date there has been poor translation of immunotherapies from rodent models to treatment of progressive multiple sclerosis (MS). In the robust, relapsing Biozzi ABH mouse model of MS, using a combination of a transient deletion of T cells followed by intravenous (i.v.) myelin antigen administration, established relapsing disease in EAE can be effectively silenced. However, when treatment was initiated in late stage chronic-relapsing disease, despite inhibition of further relapses, mice demonstrated evidence of disease progression shown by a deterioration in mobility and development of spasticity and indicates that targeting relapsing, immunological components of MS alone is unlikely to be sufficient to control progression in the late stages of MS.
authors.affiliation: Department of Neuroinflammation, Institute of Neurology, University College London, 1 Wakefield Street, London WC1N 1PJ, UK.
authors.forename: Gareth
authors.initials: G
authors.lastname: Pryce
authors.forename: Janet K
authors.initials: JK
authors.lastname: O'Neill
authors.forename: J Ludovic
authors.initials: JL
authors.lastname: Croxford
authors.forename: Sandra
authors.initials: S
authors.lastname: Amor
authors.forename: Deborah J
authors.initials: DJ
authors.lastname: Hankey
authors.forename: Emma
authors.initials: E
authors.lastname: East
authors.forename: Gavin
authors.initials: G
authors.lastname: Giovannoni
authors.forename: David
authors.initials: D
authors.lastname: Baker
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D015704:CD4 Antigens / Q000276:immunology; D002908:Chronic Disease; D004195:Disease Models, Animal; D018450:Disease Progression; D004359:Drug Therapy, Combination; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control; D007108:Immune Tolerance / Q000276:immunology*; D007275:Injections, Intravenous; D008212:Lymphocyte Depletion; D051379:Mice; D038602:Mice, Biozzi; D016513:Mice, SCID; D020528:Multiple Sclerosis, Chronic Progressive / Q000276:immunology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000276:immunology* / Q000517:prevention & control; D018991:Myelin Proteolipid Protein / Q000008:administration & dosage / Q000276:immunology; D055502:Secondary Prevention; D013116:Spinal Cord / Q000166:cytology / Q000276:immunology / Q000637:transplantation; D013154:Spleen / Q000166:cytology / Q000276:immunology / Q000637:transplantation
chemical_list: D000911:Antibodies, Monoclonal; D015704:CD4 Antigens; D018991:Myelin Proteolipid Protein